IRCT20220111053692N17
Recruiting
未知
Bioequivalence study of Empagliflozin Metformin 12.5-1000 mg (Tehran chemie Pharmaceutical Company) versus Synjiardy (Boehringer Ingelheim) Tablet after single oral dosing in healthy volunteers
Tehran Chemie Pharmaceutical Company0 sites24 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Bioequivalence study of Empagliflozin Metformin 12.5-1000 mg (Tehran Chemie Pharmaceutical Company) versus Synjiardy(Boehringer Ingelheim) Tablet after single oral dosing in healthy volunteers.
- Sponsor
- Tehran Chemie Pharmaceutical Company
- Enrollment
- 24
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Being at the age of 18 to 55 years old.
- •Weight in range of 10 % of proper body weight.
- •All volunteers should be in a good health condition on the basis of medical history, physical examination, routine blood test.
- •Possessing negative test for hepatitis B surface antigen (HBs\-Ag), Antihepatitis\-C antibody (anti\-HCV) and anti\-HIV.
Exclusion Criteria
- •Volunteers with hypersensitivity to Empagliflozin metformin
- •Those with known history of drug abuse, alcohol consuming or cigarette smoking.
- •Taking medications that have drug interactions with Empagliflozin metformin until one month before studying.
- •Disinclination to take the test.
- •Blood donation or blood loss of more than 200 ml in the past month.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Bioequivalence study of Empagliflozin/Metformin12.5/1000 mgThis study is performed on healthy volunteers and drug concentration in plasma is determined..IRCT20200105046010N93Faran Pharmed company24
Recruiting
Not Applicable
Investigating the in vivo bioequivalence of Empagliflozin /Metformin tabletIRCT20210519051345N31Tabriz University of Medical Sciences24
Completed
Phase 1
Bioequivalence Study in Healthy Volunteers for Empagliflozin/Metformin Fixed Dose Combination Compared to Separate TabletsHealthyNCT02028767Boehringer Ingelheim32
Completed
Not Applicable
Comparative in vivo evaluation of 2 Empagliflozin 12.5 Combined Tablet with Metformin 1000 mg Tablet formulations.IRCT20180620040164N52Darou darman Pars Co.24
Completed
Not Applicable
Bioequivalence study of Empagliflozin 5 mg/ Metformin 1000 mg film coated tablet manufactured by Modava Pharmaceutical CompanyIRCT20130313012810N22Modava Pharmaceutical Company24